Cochrane · systematic review · CD004760
Creatine for treating muscle disorders
Kley, RA, Tarnopolsky, MA, Vorgerd, M · Cochrane Database of Systematic Reviews · 2013 · Cochrane Library
SoF tableOnly the outcomes this review put in its Summary of Findings table are listed (the Cochrane Handbook caps them at about seven per comparison). Its other analyses are not shown here.
Questions
13
current version
GRADE rated
10
No studies
0
Included studies
NR
No studies 0 · 0%Ungraded 3 · 23.1%Very low 0 · 0%Low 0 · 0%Moderate 1 · 7.7%High 9 · 69.2%
Ungraded means an effect was reported without a GRADE rating; it is not a gap. No studies means the review found nothing to answer the question. The six categories are a display order, not a score.
Questions and results
Current version onlyCreatine for treating muscular dystrophies
Population: patients with muscular dystrophies
| Outcome | Effect | Evidence | Status / GRADE |
|---|---|---|---|
Maximum voluntary contraction in dystrophinopathies % | no estimate extracted | 3 studies · 121 participants | High |
Maximum voluntary contraction in myotonic dystrophy type 1 % | no estimate extracted | 2 studies · 76 participants | Moderate Downgraded: inconsistency |
Maximum voluntary contraction in myotonic dystrophy type 2 % | no estimate extracted | 1 study · 10 participants | High |
Adverse events | no estimate extracted | 8 studies · 261 participants | High |
Global assessment of improvement felt better | RR 4.51 [2.33, 8.74] | 4 studies · 183 participants | High |
Creatine for treating metabolic myopathies
Population: patients with metabolic myopathies
| Outcome | Effect | Evidence | Status / GRADE |
|---|---|---|---|
Maximum voluntary contraction in mitochondrial diseases % | no estimate extracted | 2 studies · 38 participants | High |
Maximum voluntary contraction in glycogen storage disease type V % | no estimate extracted | 1 study · 28 participants | High |
Impairment of activities of daily living (ADL) in glycogen storage disease type V Visual numeric scale. Scale from: 1 to 10. | no estimate extracted | 1 study · 19 participants | High |
Adverse events in mitochondrial diseases | no estimate extracted | 3 studies · 38 participants | Ungraded |
Adverse events in glycogen storage disease type V | no estimate extracted | 2 studies · 28 participants | Ungraded |
Creatine for treating idiopathic inflammatory myopathies
Population: patients with idiopathic inflammatory myopathies
| Outcome | Effect | Evidence | Status / GRADE |
|---|---|---|---|
Aggregate functional performance time (AFPT), intention‐to‐treat analysis % | no estimate extracted | 1 study · 37 participants | High |
AFPT, valid compliant completer analysis % | no estimate extracted | 1 study · 29 participants | High |
Adverse events | no estimate extracted | 1 study · 37 participants | Ungraded |
Creatine for treating muscular dystrophies
Population: patients with muscular dystrophies
| Outcome | Effect | Evidence | Status / GRADE |
|---|---|---|---|
Maximum voluntary contraction in dystrophinopathies % | no estimate extracted | 3 studies · 121 participants | High |
Maximum voluntary contraction in myotonic dystrophy type 1 % | no estimate extracted | 2 studies · 76 participants | Moderate Downgraded: inconsistency |
Maximum voluntary contraction in myotonic dystrophy type 2 % | no estimate extracted | 1 study · 10 participants | High |
Adverse events | no estimate extracted | 8 studies · 261 participants | High |
Global assessment of improvement felt better | RR 4.51 [2.33, 8.74] | 4 studies · 183 participants | High |
Creatine for treating metabolic myopathies
Population: patients with metabolic myopathies
| Outcome | Effect | Evidence | Status / GRADE |
|---|---|---|---|
Maximum voluntary contraction in mitochondrial diseases % | no estimate extracted | 2 studies · 38 participants | High |
Maximum voluntary contraction in glycogen storage disease type V % | no estimate extracted | 1 study · 28 participants | High |
Impairment of activities of daily living (ADL) in glycogen storage disease type V Visual numeric scale. Scale from: 1 to 10. | no estimate extracted | 1 study · 19 participants | High |
Adverse events in mitochondrial diseases | no estimate extracted | 3 studies · 38 participants | Ungraded |
Adverse events in glycogen storage disease type V | no estimate extracted | 2 studies · 28 participants | Ungraded |
Creatine for treating idiopathic inflammatory myopathies
Population: patients with idiopathic inflammatory myopathies
| Outcome | Effect | Evidence | Status / GRADE |
|---|---|---|---|
Aggregate functional performance time (AFPT), intention‐to‐treat analysis % | no estimate extracted | 1 study · 37 participants | High |
AFPT, valid compliant completer analysis % | no estimate extracted | 1 study · 29 participants | High |
Adverse events | no estimate extracted | 1 study · 37 participants | Ungraded |